For what's its worth.
The company: Allergan Inc.
Leadership: David E.I. Pyott, chief executive since 1998
Revenue: $5.8 billion in 2012
Net income: $1.1 billion in 2012
Stock price: $108.60 at Friday's close
52-week range: $81.28 to $109.31
P/E ratio: 22.8 based on 2013 estimated earnings
Annual dividend: 5 cents, a current yield of about 0.2%
This is the company that makes Botox. The wrinkle-erasing drug is Allergan's top-selling product — with sales expected to reach $2 billion in 2013.
But there's more to Allergan than wrinkle medicine. The self-described "multi-specialty healthcare company" also sells breast implants, a prescription drug that enhances eyelashes, a line of ophthalmic pharmaceuticals and, at least for now, the Lap-Band weight-loss device.
The company reported record sales of $5.8 billion in 2012 and expects robust sales again this year —$5.9 billion to $6.2 billion. Its stock hit an all-time high of $109.31 on Feb. 19]
Let's not forget Allergen. They got deep pockets and a foot in the game.